for the treatment of chronic immune thrombocytopenia (ITP); REZLIDHIA ® (olutasidenib) for the treatment of relapsed or ...

In people with secondary AML, these changes occur in immature myeloid blood cells due to previous cancer treatment or another blood disorder. Myeloid blood cells become: platelets red blood cells ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their ...

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

But everything changed when he was diagnosed with acute myeloid leukemia (AML), a fast-growing cancer of the ... Throughout ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in ...